MedTrace Logo

PENG Block for Total Hip Arthroplasty

NCT05944380 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 556

Last updated 2023-07-13

No results posted yet for this study

Summary

This randomized, double-blinded, placebo-controlled trial seeks to evaluate the efficacy of the pericapsular nerve group block on postoperative rehabilitation.

Conditions

  • Hip Osteoarthritis
  • Hip Arthropathy
  • Hip Disease
  • Hip Pain Chronic

Interventions

DRUG

Ropivacaine 0.5% Injectable Solution

20 mL 0.5% ropivacaine will be injected for the PENG block

DRUG

0,9% normal saline

20 mL 0.9% normal saline will be injected for the PENG block

Sponsors & Collaborators

  • Poznan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Małgorzata Domagalska, PhD · Department of Palliative Medicine, University of Medical Sciences, Poznań, Poland

  • Zbigniew Żaba, PhD · Department of Emergency Medicine Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2022-06-23
Completion
2023-01-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05944380 on ClinicalTrials.gov